JH-X-119-01

JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice[1]. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM[2].

Product Specifications

CAS Number

[2227368-54-7]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jh-x-119-01.html

Purity

99.03

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C=C)NC1=CC=CC(C(NC2=CC=C(NC(C3=NC(C4=CC=NN4)=CC=C3)=O)C=C2)=O)=C1

Molecular Formula

C25H20N6O3

Molecular Weight

452.46

Precautions

H315, H319

References & Citations

[1]Bin Pan, et al. Selective inhibition of interleukin-1 receptor-associated kinase 1 ameliorates lipopolysaccharide-induced sepsis in mice. Int Immunopharmacol. 2020 Aug;85:106597.|[2]John M Hatcher, et al. Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Med Chem Lett. 2020 Oct 9;11 (11) :2238-2243.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

IRAK1; IRAK4

Citation 01

JCI Insight. 2022 Jul 8;7 (13) :e149825.|The Ohio State University. 2025.|Emerg Microbes Infect. 2024 Dec;13 (1) :2300452.|Sci Adv. 2024 Nov 29;10 (48) :eadq8122.|University of Louisville. 2023 May 24.